Clinical Stages May Predict Outcomes in CLL
Published: 2018-07-20 |
Author: James Nam, PharmD |
Source: Cancer Therapy Advisor
Determining the clinical stage of patients with chronic lymphocytic leukemia (CLL) may be an effective prognostic marker for time to next therapy (TTNT) and overall survival (OS), according to a study published in Clinical Lymphoma Myeloma and Leukemia.
Response to therapy is one of the most important predictors of survival among patients with cancer. The authors hypothesized that clinical stage determined by the Binet staging system, particularly the heterogeneous International Workshop on CLL (IWCLL) partial response (PR) category, could be an accurate response surrogate among this patient population.
For this study, researchers retrospectively assessed the outcomes of 229 patients with CLL previously treated with chemotherapy and/or immunotherapy. Using the IWCLL criteria, PRs according to changes in Binet clinical stage were separated into the PR-A, PR-B, and PR-C subcategories. Patients who had PR-B and PR-C were placed into the same group due to the small number of patients in these categories.
The median follow-up period was 91 months. Overall, 92 patients achieved an IWCLL PR during the course of treatment and 66 had responses that could be subcategorized according to Binet clinical staging; 76% (50) and 24% (16) had Binet stage A and B/C, respectively. The median number of previous lines of therapy was 2.
Results show that patients who had a PR-A at time of response evaluation had a significantly longer median TTNT of 26 months compared with 11 months among patients who had PR-B/C.